Fewer Discontinuations With Infliximab for UC Maintenance Tx Fewer Discontinuations With Infliximab for UC Maintenance Tx
Researchers compared the rates of discontinuation after 1 year due to lack of efficacy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Adalimumab + Methotrexate Beneficial for Pediatric Crohn Disease
THURSDAY, April 27, 2023 -- For pediatric Crohn disease (PCD) patients, treatment with methotrexate combined with adalimumab, but not infliximab, is associated with a reduction in treatment failure, according to a study published online March 31 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 27, 2023 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports Q1 2023 Results
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)2...
Source: Johnson and Johnson - April 18, 2023 Category: Pharmaceuticals Tags: Financial Source Type: news
Should You Buy The Botox Maker Over Johnson & Johnson Stock?
We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. Although AbbVie is trading at 4.8x trailing revenues compared to 4.2x for J&J, this gap in valuation looks justified, given the…#abbvie #johnsonjohnson #jnj #remicade #allergan #humira #crohn #botox #rinvoq #abbvierevenue (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2023 Category: Consumer Health News Source Type: news
Johnson & Johnson and Janssen Biotech settle Remicade class action lawsuit after 6 years
The lawsuit alleged Johnson& Johnson acted improperly to block competition for its blockbuster drug Remicade. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 20, 2023 Category: American Health Authors: John George Source Type: news
Is A Rise Imminent For Johnson & Johnson Stock After An 8% Fall In A Month?
Johnson & Johnson stock (NYSE: JNJ) is down 8% in a month, underperforming the broader markets, with the S&P 500 index up 6%. In a recent development, a U.S. appeals court rejected J&J’s attempted use of Texas Two-Step bankruptcy strategy to offload nearly 40,000 lawsuits for its talc products.…#johnsonjohnson #jjs #texastwostep #remicade #consumerhealthcare #eps #jnj #johnsonjohnsons #peercomparisons #vicor (Source: Reuters: Health)
Source: Reuters: Health - February 2, 2023 Category: Consumer Health News Source Type: news
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news
What to Know About Infusion Therapy for IBD
The human gastrointestinal tract can be a hostile place for visitors. It’s filled with digestive acids and microorganisms that rapidly break down swallowed bits of food, and it can be just as rough on non-food molecules. That includes some of the latest drugs for the treatment of inflammatory bowel disease (IBD). “Some medications that target the immune system don’t work if they’re swallowed because your gut would digest them like a piece of steak,” says Dr. Gilaad Kaplan, a gastroenterologist, IBD researcher, and professor of medicine at the University of Calgary in Canada. “You have to...
Source: TIME: Health - January 10, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Source Type: news
IBD: Limited Protection Against Omicron With Third Vaccine Dose IBD: Limited Protection Against Omicron With Third Vaccine Dose
Patients with IBD taking infliximab or tofacitinib may be more vulnerable to Omicron infection even after a third dose of a COVID-19 mRNA vaccine.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 9, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Infliximab Maintenance Home Infusion Appears Safe
(MedPage Today) -- ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher reported here.
Of 863 patients... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 7, 2022 Category: Gastroenterology Source Type: news
Retention High With Biosimilar-to-Biosimilar Switch for Arthritis Retention High With Biosimilar-to-Biosimilar Switch for Arthritis
Danish investigators studied how a government-mandated switch from one infliximab biosimilar to another affected patients with inflammatory arthritis.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Anti-Inflammatory Agents May Have Role in COVID-19 Pneumonia
(MedPage Today) -- WASHINGTON -- Use of the anti-inflammatory agents infliximab (Remicade) and abatacept (Orencia) added to standard of care showed a hint of improvement in outcomes for patients hospitalized with COVID-19 pneumonia, according... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 25, 2022 Category: Infectious Diseases Source Type: news
Infliximab in Patients With Juvenile-Onset Spondyloarthritis Infliximab in Patients With Juvenile-Onset Spondyloarthritis
Is infliximab an effective therapeutic option for patients with juvenile-onset spondyloarthritis who don ' t adequately respond to conventional treatment?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Low Risk for IBD Relapse After Switch From IV to Subcutaneous Infliximab
(MedPage Today) -- Switching from intravenous to subcutaneous infliximab (Remicade) was safe and effective for patients with inflammatory bowel disease (IBD) in clinical remission, an observational study in France showed.
Among 133 patients treated... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 19, 2022 Category: Gastroenterology Source Type: news
